EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Hamilton Thorne's enterprise value is C$371.1 Mil.
Hamilton Thorne's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was C$103.4 Mil. Therefore, Hamilton Thorne's EV-to-Revenue for today is 3.59.
The historical rank and industry rank for Hamilton Thorne's EV-to-Revenue or its related term are showing as below:
TSX:HTL'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.96 Med: 3.27 Max: 5.59
Current: 3.59
During the past 13 years, the highest EV-to-Revenue of Hamilton Thorne was 5.59. The lowest was 0.96. And the median was 3.27.
TSX:HTL's EV-to-Revenue is ranked worse than 52.61% of 825
companies
in the Medical Devices & Instruments industry
Industry Median: 3.38
vs TSX:HTL: 3.59
As of today (2024-12-14), Hamilton Thorne's stock price is C$2.24.
Hamilton Thorne's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was C$0.68. Therefore, Hamilton Thorne's PS Ratio for today is 3.31.
Hamilton Thorne EV-to-Revenue Historical Data
The historical data trend for Hamilton Thorne's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Hamilton Thorne's EV-to-Revenue
For the Medical Devices subindustry, Hamilton Thorne's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hamilton Thorne's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hamilton Thorne's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Hamilton Thorne's EV-to-Revenue falls into.
Hamilton Thorne's current Enterprise Value is C$371.1 Mil.
Hamilton Thorne's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$103.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hamilton Thorne (TSX:HTL) EV-to-Revenue Explanation
Hamilton Thorne's share price for today is C$2.24.
Hamilton Thorne's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.68.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hamilton Thorne EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Hamilton Thorne's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Hamilton Thorne Ltd is engaged in providing precision instruments, consumables, software, and services that reduce cost, increase productivity, improve results, and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. The company markets its products and services under the Hamilton Thorne, Gynemed, and Embryotech Laboratories brands, through its growing sales force and distributors. The company's customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments. It has a single reporting segment being Engaged in Sales to the ART, Research, and Cell Biology Markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSX:HTL has been successfully added to your 